FDA approves Qfitlia to cut bleeding episodes in patients with hemophilia
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
BioPharma Dive6d
FDA approves first-of-its-kind RNA drug for hemophilia
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.
Baylor College of Medicine2d
Mutated blood cells define clinical risks in Langerhans cell histiocytosis, paving the way for better diagnosis and treatment
A nationwide team led by researchers at Baylor College of Medicine, Texas Children’s Hospital and UPMC Children's Hospital of ...
Hemophilia News Today9d
Bleeding, blood clot-related events in US tied to acquired hemophilia
About 30% of people hospitalized due to acquired hemophilia have a bleeding event, while 17% have a blood clot-related ...
Hemophilia News Today2d
Hemophilia patients’ bone health screening rates low at US HTCs
Researchers said a better understanding of barriers to bone health in hemophilia and VWD is needed, and guidelines should be ...
The American Journal of Managed Care7d
FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B
Fitusiran offers a 90% reduction in bleeding rates for hemophilia A or B with less frequent dosing than existing options. Phase 3 ATLAS trials showed significant efficacy, with many participants ...
The Eagle-Tribune6d
Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia Therapy
Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia ...
FiercePharma28d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Overall, the near-term success of those ambitions will come down to a handful of new drug launches and a sickle cell disease ... Beyond hemophilia, the next frontier for Novo’s blood disorder ...